Neumora Therapeutics, Inc. NMRA 深 沪
已收盘 10-31 16:00:00 美东时间
3.02
+0.090
+3.07%
华盛通- 最 高3.25
- 今 开3.00
- 成交量 458.16万股
- 最 低 2.82
- 昨 收 2.93
- 总市值 4.89亿
- 52周最高 14.09
- 市盈率 静 --
- 换手率 2.83%
- 52周最低 0.611
- 委 比 99.18%
- 总股本 1.62亿
- 历史最高 21.00
- 量 比 0.78
- 振 幅 14.68%
- 历史最低 0.611
- 每 手 1
- 风险率 3.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
10-29 09:25
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
Neumora Reports Positive Preclinical Results for NMRA-215
Neumora Therapeutics, Inc. ( ($NMRA) ) has provided an update. On October 27, 2...
10-27 18:58
Neumora Announces Preclinical Data For NMRA-215, Showing Weight Loss Of Up To 19% As Monotherapy With Semaglutide-Like Induction; Plans To Initiate Phase 1 Clinical Study In Q1 2026
NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglutideClass-leading
10-27 18:36
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
Neumora Therapeutics announced positive preclinical data for NMRA-215, a potentially best-in-class, brain-penetrant, oral NLRP3 inhibitor, showing up to 19% weight loss as monotherapy and up to 26% in combination with semaglutide. NMRA-215's strong brain penetration and pharmacology contribute to its class-leading weight loss. Phase 1 clinical studies are planned for Q1 2026.
10-27 10:30
美股牛股 | VTYX大涨71%！新药研究取得积极结果；SEV转型为公益公司，涨近58%
VTYX大涨71%！新药在肥胖和心血管风险因素患者中的2期研究取得积极结果；SEV转型为公益公司，涨近58%>>
10-24 15:16
Neumora Therapeutics to Host Virtual R&D Day on October 27
Neumora Therapeutics will host a virtual R&D Day on October 27, 2025, to discuss its pipeline, including NMRA-215 (NLRP3 inhibitor for obesity), NMRA-511 (potential treatment for Alzheimer's disease agitation), its M4 franchise, and navacaprant (kappa opioid receptor antagonist in Phase 3). The event will provide updates on preclinical and clinical data, with registration available via the company's website.
10-01 11:00
JP Morgan Downgrades Neumora Therapeutics to Underweight
JP Morgan analyst Tessa Romero downgrades Neumora Therapeutics (NASDAQ:NMRA) from Neutral to Underweight.
09-16 18:39
Neumora Therapeutics to Participate in Upcoming Conferences in September
Neumora Therapeutics will attend three investor conferences in September 2025 to discuss its seven therapeutic programs targeting underserved diseases. Management will participate in one-on-one meetings at the Wells Fargo Healthcare Conference on September 4 in Boston and the Morgan Stanley Global Healthcare Conference on September 8 in New York. They will also engage in a fireside chat at the H.C. Wainwright Global Investment Conference on Septe...
09-02 11:00
Neumora Therapeutics GAAP EPS of -$0.33
Neumora Therapeutics press release (NASDAQ:NMRA): Q2 GAAP EPS of -$0.33. Cash Position: As of June 30, 2025, Neumora had cash, cash equivalents and marketable securities of $217.6 million. Financial G...
08-07 05:53
